Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

2 articles from the last 90 days matching "2026"

🔴 BreakingDrug approvalOPENFDAApr 4

FDA Approves FOUNDAYO (ORFORGLIPRON) — New Treatment Available

The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.

WHY IT MATTERSWithout information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.
💬 Ask your doctorRead →
🔴 BreakingDrug approvalOPENFDAApr 3

FDA Approves LIFYORLI (RELACORILANT) — New Treatment Available

The FDA has approved a new medication called LIFYORLI (relacorilant) made by Corcept Therapeutics. This drug was officially approved on March 25, 2026. LIFYORLI is a new treatment option that is now available for patients who need it.

WHY IT MATTERSThis approval marks the availability of a new treatment option for patients with Cushing's syndrome, a serious hormonal disorder where the body produces too much cortisol.
→ You can act on thisCushing's syndromeRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases